Debonding modes of failure are undesired because they usually happen well before the section’s predicted ultimate strength is reached, which causes the FRP to be underutilized and reduces the ...

Ideas to reduce carbon emissions often revolve around renewable power, electric vehicles and energy efficiency. But there’s another, less colorful character that’s often overlooked: cement. “Cement ...

Using silicate rocks like basalt instead of limestone for cement could reduce associated carbon dioxide emissions by more than 80% “There is the potential to solve a climate problem as big as cars ...

(Santa Barbara, Calif.) — Ideas to reduce carbon emissions often revolve around renewable power, electric vehicles and energy efficiency. But there’s another, less colorful character that’s often ...

Section 1. Purpose. The American people expect their Government to operate with integrity, efficiency, and transparency. For too long, Federal procurement has tolerated unpredictable costs, bloated ...

A thermoelectric generator with a shape that no human designer would likely have imagined has now been created by a computer—and it performs more than eight times better than conventional designs.

Take an exclusive look inside the cockpit of a revolutionary hybrid machine designed for ultimate aerodynamic efficiency and record-breaking speeds. This first-person perspective highlights the unique ...

Senior services, child care, business vitality and affordable housing dominated a forum with four Basalt Town Council hopefuls on Monday. The candidates displayed a spectrum of local governance ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...